Statement: None of the patients in Cohort 1 of the primary trial suffered from Hypotension.
Primary_evidence: Adverse Events 1:   Total: 18/50 (36.00%)   Hypotension 0/50 (0.00%)   Bradycardia 0/50 (0.00%)   Cardiac Arrest 1/50 (2.00%)   Diarrhea 2/50 (4.00%)   Pain - Abdominal 1/50 (2.00%)   Hemorrhage - GI 1/50 (2.00%)   Vomiting 0/50 (0.00%)   Nausea 0/50 (0.00%)   Dehydration 0/50 (0.00%)   Diverticular Abscess 1/50 (2.00%)   Failure to Thrive 1/50 (2.00%)   Fever 0/50 (0.00%) Adverse Events 2:   Total: 22/52 (42.31%)   Hypotension 1/52 (1.92%)   Bradycardia 1/52 (1.92%)   Cardiac Arrest 0/52 (0.00%)   Diarrhea 0/52 (0.00%)   Pain - Abdominal 0/52 (0.00%)   Hemorrhage - GI 1/52 (1.92%)   Vomiting 1/52 (1.92%)   Nausea 1/52 (1.92%)   Dehydration 1/52 (1.92%)   Diverticular Abscess 0/52 (0.00%)   Failure to Thrive 0/52 (0.00%)   Fever 1/52 (1.92%)